Accueil   Diary - News   All news Alphanosos


Alphanosos has been incorporated in 2014 by Dr Pascal Mayer (former Glaxo-Wellcome, Serono and Biofilm Control) and Daniel Valtueña Maestre (former Serono, Filaxis).We started operations in May 2015 in premises rented from Biopôle Clermont-Limagne in Riom, France. We are financed by private investors and public support (BpiFrance and Conseil Régional Auvergne-Rhône-Alpes) and are currently conducting a second round of fund raising.


We leverage our disruptive, Artificial Intelligence (AI) based proprietary discovery platform to discover and patent active ingredients and products based on patentable mixes of edible plant extracts with a history of safe human consumption to bring, rapidly, new human and animal therapeutic solutions, with a superior efficacy and reduced risks of side effects relative to traditional mono-compound approaches. We concentrate our discovery efforts on the selective elimination of deleterious cells and micro-organisms, including their biofilms, with an initial focus on genuine alternatives to antibiotics and anti-cancer products.


We have just undergone international extension of our first patent on antibacterial actives with efficacies against several multi-resistant bacteria and their biofilm, in particular Staphylococcus aureus, epidermidis and pseudintermedius (including MRSA) and Neisseria gonorrhoeae, and 2 among the 3 carbapenem resistant organisms for which WHO sees the discovery of new treatments as critical : Pseudomonas aeruginosa and Acinetobacter baumannii.


Based on these patent pending alternatives to antibiotics and depending on their composition and action on the biofilm, our product development pipeline comprises:

  • Veterinary hygiene product adapted to pyoderma situations, available by end 2018.
  • Medical Device (IIa in EU) and Botanical Drug (USA) adapted to skin irritation situations which are exacerbated by the presence of persistent (biofilm) Staphylococcus aureus (eczema, dermatitis, psoriasis, acne,…), available end 2019.
  • Medical Device (IIa in EU) and Botanical Drug (USA) to prevent implantable device infection (prosthetic joints, TIVADs), IND scheduled for 2021.
  • Products adapted to chronic rhino-sinusitis (spray) and chronic wounds (dressing), scheduled in 2020-21.
  • Veterinary hygiene product for dogs adapted to otitis, scheduled for 2020.
  • « Botanical drug » (USA) as alternatives to antibiotics for preventing and treating cryptic and acute infections and as antibiotic enhancer co-drugs.


We are of course pursuing discovery campaigns for additional novel alternatives to antibiotics, in particular against enterobacteria. These will allow us to further focus on cryptic infections involved in chronic inflammatory conditions linked to the inception of certain cancers and certain immunological diseases, in particular certain auto-immune diseases.


For all these projects, we are actively looking for partners (and licensees) for the commercialization and the development of products, as well as for leveraging our AI algorithms and knowhow through discovery partnerships outside our core therapeutic areas, for instance pain, addiction, viral infection, and in the food and environmental sectors. Accordingly, we have already entered into two license agreements in the cosmetic domain.



Pascal Mayer, PhD - CEO and co-founder

Alphanosos S.A.S. , 20-22 rue Henri et Gilberte Goudier, 63200 Riom France, +33 (0)6 59 85 68 81 / +33 (0)9 82 21 65 06